| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.27 | 0.08 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.084 | 0.08 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.09 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 0.09 |